TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference
Brief Summary: After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Combination Aliskiren / Enalapril; Type: EXPERIMENTAL; Interventions: Drug: Enalapril, Drug: Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Combination Aliskiren / Enalapril, Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren, Combination Aliskiren / Enalapril
D: Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Matching placebo to Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Matching placebo to Ramipril | Arm Label: Placebo to Ramipril; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Ramipril | Arm Label: Placebo to Aliskiren; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Matching placebo to Aliskiren; Assigned to Arm(s): Placebo to Aliskiren, Ramipril | Intervention Type: DRUG; Name: Matching placebo to Ramipril; Assigned to Arm(s): Aliskiren, Placebo to Ramipril

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension
Brief Summary: To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction
Brief Summary: This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.


Options:
A: Intervention Type: DRUG; Name: Famciclovir; Assigned to Arm(s): N/A
B: Arm Label: Famciclovir; Type: EXPERIMENTAL; Interventions: Drug: Famciclovir, Drug: Placebo matching valacyclovir | Arm Label: Valacyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valacyclovir, Drug: Placebo matching famciclovir | Intervention Type: DRUG; Name: Famciclovir; Assigned to Arm(s): Famciclovir | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching famciclovir; Assigned to Arm(s): Valacyclovir | Intervention Type: DRUG; Name: Placebo matching valacyclovir; Assigned to Arm(s): Famciclovir
C: Arm Label: Standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: valacyclovir | Arm Label: High-dose; Type: EXPERIMENTAL; Interventions: Drug: acyclovir | Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): High-dose | Intervention Type: DRUG; Name: valacyclovir; Assigned to Arm(s): Standard dose
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acyclovir placebo | Intervention Type: DRUG; Name: Acyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Acyclovir placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain
Brief Summary: This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
C: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: pregabalin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (unspecified) | Intervention Type: DRUG; Name: Comparator: pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION
Brief Summary: This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib \[AG-013736\] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Axitinib [AG-013736] plus gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AG-013736, Drug: Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine | Intervention Type: DRUG; Name: AG-013736; Assigned to Arm(s): Axitinib [AG-013736] plus gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Axitinib [AG-013736] plus gemcitabine
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B
D: Arm Label: Erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Erlotinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.


Options:
A: Arm Label: 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 100 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RC-1291 HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: RC-1291 HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): RC-1291 HCl | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Brief Summary: The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodine (SPM 907) 4mg, fesoterodine 8mg, active control (tolterodine SR 4mg) or placebo during the Double-Blind Treatment Period.

Two primary efficacy variables will be assessed for submission in the United States: change in the average number of micturitions (frequency) per 24 hours and the change in the average number of urge incontinence episodes per 24 hours. For the submissions in the European Union, the first primary variable will be the change in the average number of micturitions (frequency) per 24 hours and the co-primary variable is the treatment response, based on a treatment benefit scale. All continuous variables will be measured as changes from baseline to value after 12 weeks of treatment.

The most important safety variables included the assessment of adverse events, laboratory parameters, changes in ECG, physical exams and measurement of residual urine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-3001a | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: DR-3001b | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: DR-3001a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: DR-3001b; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: ONO-8025 (KRP-197); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia
Brief Summary: Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill. Once they are more stable, research has shown that first-episode patients need to remain on their antipsychotic medication. Follow-up studies show that stopping medication prematurely is the most common cause of relapse and readmission. It is important to have new ways to help patients stay stable in the community in order for them to continue on with their rehabilitation and recovery process.

Over the last decade, new antipsychotic medications have been developed that are more effective and have fewer side effects than older antipsychotics. The new medicines are often called "atypical", and were only available by pill or capsule for long-term treatment. Most recently, one of the atypical medications - risperidone - became available as a long-acting injection that can be given once every 2 weeks.

The hypothesis of this study is that patients recovering from an acute episode and who then go on to receive a long-acting version of atypical antipsychotic medication (long-acting risperidone microspheres) will stay on their medications for longer than those who take their atypical medication (any available first-line atypical) in the oral (pill) form.


Options:
A: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: IM risperidone | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral antipsychotic medication | Intervention Type: DRUG; Name: IM risperidone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: oral antipsychotic medication; Assigned to Arm(s): Arm 2
C: Intervention Type: DRUG; Name: atypical antipsychotics:oral vs. long-acting route; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Psychoeducation; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Brief Summary: The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur every 3 weeks. Neurological function will be measured by Inflammatory Neuropathy Cause and Treatment (INCAT) scores. Patients who deteriorate or show no improvement between day 16 and month 6 will receive the alternate study drug for an additional 6 months.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2
B: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: GBS; Type: N/A; Interventions: N/A | Arm Label: NC; Type: N/A; Interventions: N/A | Arm Label: IC; Type: N/A; Interventions: N/A | Arm Label: OND; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Brief Summary: The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur every 3 weeks. Neurological function will be measured by Inflammatory Neuropathy Cause and Treatment (INCAT) scores. Patients who deteriorate or show no improvement between day 16 and month 6 will receive the alternate study drug for an additional 6 months.


Options:
A: Arm Label: IgPro10; Type: EXPERIMENTAL; Interventions: Biological: 10% liquid formulation of human immunoglobulin | Intervention Type: BIOLOGICAL; Name: 10% liquid formulation of human immunoglobulin; Assigned to Arm(s): IgPro10
B: Arm Label: NPB-01; Type: EXPERIMENTAL; Interventions: Drug: NPB-01 | Intervention Type: DRUG; Name: NPB-01; Assigned to Arm(s): NPB-01
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2
D: Arm Label: IgPro20 low dose; Type: EXPERIMENTAL; Interventions: Biological: IgPro20 (low dose), Biological: IgPro10 | Arm Label: IgPro20 high dose; Type: EXPERIMENTAL; Interventions: Biological: IgPro10, Biological: IgPro20 (high dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: IgPro10 | Intervention Type: BIOLOGICAL; Name: IgPro20 (low dose); Assigned to Arm(s): IgPro20 low dose | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: IgPro10; Assigned to Arm(s): IgPro20 high dose, IgPro20 low dose, Placebo | Intervention Type: BIOLOGICAL; Name: IgPro20 (high dose); Assigned to Arm(s): IgPro20 high dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Diabetic Cardiovascular Complications With Vitamin E 400 IU Treatment to High Risk Patients by Haptoglobin Phenotype (I CARE - Israel Cardiovascular Atherosclerosis Risk and Vitamin E)
Brief Summary: The purpose of this study is to determine whether Vitamin E treatment to Diabetic patients, who carry the Haptoglobin 2-2 Phenotype, prevents cardiovascular complications such as acute MI and Stroke.


Options:
A: Intervention Type: DRUG; Name: Natural source Vitamin E 400IU/day; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
D: Arm Label: AREDS participants; Type: N/A; Interventions: N/A

Answer: A